Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Lianjie Miao
The current state of healthcare is shifting due to the fast developing field of biotechnology, which has the potential to revolutionize how illnesses are identified and treated. Healthcare biotechnology has been the topic of many great efforts, and our understanding of it has grown significantly. New biomedical paradigms are developing as a result of the most recent developments in genetics and molecular biology, igniting fresh research into brandnew solutions for human health and wellbeing. However, an exciting obstacle still exists in the practical translational development of revolutionary technological discoveries. Only a small number of biotech breakthroughs have led to brand-new, revolutionary treatments and technologies for healthcare. We shall describe the clinical translational development atmosphere for biotechnology in healthcare in this paper. Notable medical biotechnology achievements and translational promotions, including historical findings and novel perspectives are carefully covered. More groundbreaking biotech ideas are about to be translated into commercial products to bring about positive health gains, despite the fact that there are nevertheless numerous obstacles in the bench-to-bedside translational development process. This is being carried out with a tight multitude of collaboration among research institutes, healthcare providers, and industry partners.